13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • Please share this website:
    Research home > Beat Cancer Project > Infrastructure: Providing the tools that enable breakthrough to happen

    Infrastructure: Providing the tools that enable breakthrough to happen

    Professor David Callen
    • Donor Funding: $10,000
    • Cancer Type: All Cancers
    • Funded in: 2013
    • Professor David Callen
      The University of Adelaide

    BIORAD CFX Connect Real-time PCR Detection System

    Our research

    This infrastructure grant provided critical capacity to undertake a variety of cancer-related projects. These range from investigating new approaches for treatment of sarcomas (cancers) to identifying how vitamin D reduces the incidence of breast cancer.

    What we aim to achieve 

    We have a number of on-going projects. These include developing new effective treatments for patients with solid tumours and reducing the rate of breast cancer by maintaining optimal levels of vitamin D.

    Our next steps and milestones 

    Our goals in the next three years are to identify a new lead compound that can be developed as a solid cancer therapeutic and to provide a rational understanding of how high levels of vitamin D can reduce breast cancer risk.

    What motivates me

    Two major factors are mentoring postgraduate students who will be the next generation of cancer researchers and a love of research which is directed towards curing cancer.

    My message to supporters

    Funding from Cancer Council SA donors provided a critical piece of equipment that contributes to the ongoing cancer research of several different projects that aim to improve the treatment of cancer.


  • Apply for funding

    Apply for funding

    Find out more about applications for funding.

  • Cancer statistics

    Cancer statistics

    Access the latest cancer statistics for South Australia

  • Clinical trials

    Clinical trials

    Access the list of current clinical trials taking place in South Australia.